CTSO Long Call Strategy

CTSO (Cytosorbents Corporation), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

CTSO (Cytosorbents Corporation) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $35.8M, a beta of 1.44 versus the broader market, a 52-week range of 0.499-1.39, average daily share volume of 80K, a public-listing history dating back to 2006, approximately 149 full-time employees. These structural characteristics shape how CTSO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.44 indicates CTSO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on CTSO?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current CTSO snapshot

As of May 15, 2026, spot at $0.50, ATM IV 32.10%, IV rank 3.45%, expected move 9.20%. The long call on CTSO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on CTSO specifically: CTSO IV at 32.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a CTSO long call, with a market-implied 1-standard-deviation move of approximately 9.20% (roughly $0.05 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CTSO expiries trade a higher absolute premium for lower per-day decay. Position sizing on CTSO should anchor to the underlying notional of $0.50 per share and to the trader's directional view on CTSO stock.

CTSO long call setup

The CTSO long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CTSO near $0.50, the first option leg uses a $0.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CTSO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CTSO shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$0.50N/A

CTSO long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

CTSO long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on CTSO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on CTSO

Long calls on CTSO express a bullish thesis with defined risk; traders use them ahead of CTSO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

CTSO thesis for this long call

The market-implied 1-standard-deviation range for CTSO extends from approximately $0.45 on the downside to $0.55 on the upside. A CTSO long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CTSO IV rank near 3.45% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CTSO at 32.10%. As a Healthcare name, CTSO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CTSO-specific events.

CTSO long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CTSO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CTSO alongside the broader basket even when CTSO-specific fundamentals are unchanged. Long-premium structures like a long call on CTSO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CTSO chain quotes before placing a trade.

Frequently asked questions

What is a long call on CTSO?
A long call on CTSO is the long call strategy applied to CTSO (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CTSO stock trading near $0.50, the strikes shown on this page are snapped to the nearest listed CTSO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are CTSO long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CTSO long call priced from the end-of-day chain at a 30-day expiry (ATM IV 32.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a CTSO long call?
The breakeven for the CTSO long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CTSO market-implied 1-standard-deviation expected move is approximately 9.20%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on CTSO?
Long calls on CTSO express a bullish thesis with defined risk; traders use them ahead of CTSO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current CTSO implied volatility affect this long call?
CTSO ATM IV is at 32.10% with IV rank near 3.45%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related CTSO analysis